| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10137548 | International Immunopharmacology | 2018 | 9 Pages |
Abstract
Anti-interleukin-5 therapy appears to be a safe and effective treatment for asthma patients with respect to pulmonary lung function, adverse events and AQLQ scores, and do not increase asthmatic exacerbations. Our network meta-analysis in patients with asthma suggests that reducing adverse events benefits due to reslizumab, and pulmonary lung function benefits as well as good AQLQ scores are seen with respect to the three antibodies. Network meta-analysis indicates the probability that the best anti-interlukin-5 therapy for asthma patients might be reslizumab, but further trials are required to determine the most effective asthma treatment drug.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Lu-Lu He, Lei Zhang, Lei Jiang, Feng Xu, Dong-Sheng Fei,